Opinion|Videos|May 31, 2024
Insights from CARTITUDE-4 and KarMMa-3 in R/R MM
Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Briefly review the CARTITUDE-4 trial that led to cilta-cel’s approval in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM).
- Please comment on the patient population – intention-to-treat vs patients treated.
- What was the rationale for the difference? How does it affect your interpretation of the data?
- How did the safety outcomes compare with other CARTITUDE trials?
- Please share your real-world experience.
- Please review data from KarMMa-3, which led to ide-cel’s approval in earlier lines of therapy for R/R MM.
- What are thoughts on the efficacy and safety outcomes?
- Please share your real-world experience.
- How do these approvals impact the current and future treatment landscape of R/R MM?
- How might you choose one over the other?
- How does it address an unmet need?
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discusses step-up dosing workflows, REMS, staff training, caregivers, and hospital partnerships for bispecifics.
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
4
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
5